CytomX Therapeutics Inc. (CTMX)

24.82
NASDAQ : Health Technology
Prev Close 23.54
Day Low/High 23.62 / 24.92
52 Wk Low/High 13.00 / 35.00
Avg Volume 363.50K
Exchange NASDAQ
Shares Outstanding 38.96M
Market Cap 905.38M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CytomX Therapeutics To Announce Full-Year 2017 Financial Results And Host Operational Update Webcast Conference Call

CytomX Therapeutics To Announce Full-Year 2017 Financial Results And Host Operational Update Webcast Conference Call

Teleconference Scheduled for March 7, 2018, at 5:00 p.m. ET

Short Interest Increases 36.2% For CTMX

Short Interest Increases 36.2% For CTMX

The most recent short interest data has been released for the 12/29/2017 settlement date, which shows a 305,296 share increase in total short interest for CytomX Therapeutics Inc , to 1,147,408, an increase of 36.25% since 12/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Interesting CTMX Put And Call Options For August 17th

Interesting CTMX Put And Call Options For August 17th

Investors in CytomX Therapeutics Inc saw new options begin trading this week, for the August 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 221 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Commit To Buy CytomX Therapeutics At $17.50, Earn 15.4% Annualized Using Options

Commit To Buy CytomX Therapeutics At $17.50, Earn 15.4% Annualized Using Options

Investors eyeing a purchase of CytomX Therapeutics Inc shares, but tentative about paying the going market price of $21.59/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2018 put at the $17.50 strike, which has a bid at the time of this writing of $1.60.

Short Interest Expands By 26.7% For CTMX

Short Interest Expands By 26.7% For CTMX

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 324,534 share increase in total short interest for CytomX Therapeutics Inc , to 1,540,738, an increase of 26.68% since 09/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

CytomX Therapeutics To Announce Second Quarter 2017 Financial Results And Provide Mid-Year Update

CytomX Therapeutics To Announce Second Quarter 2017 Financial Results And Provide Mid-Year Update

Teleconference Scheduled for August 7, 2017, at 5:00 p.m. ET

Commit To Buy CytomX Therapeutics At $12.50, Earn 17.9% Annualized Using Options

Investors considering a purchase of CytomX Therapeutics Inc shares, but tentative about paying the going market price of $13.51/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $12.50 strike, which has a bid at the time of this writing of 95 cents.

CytomX Therapeutics Enters Oversold Territory (CTMX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

CytomX Announces Management Team Changes

Stocks Lower as Crude Slump Weighs on Energy Sector

Stocks Lower as Crude Slump Weighs on Energy Sector

Stocks snap a holding pattern to pull lower on Monday afternoon as a crude oil slump weighS on the energy sector.

TheStreet Quant Rating: D (Sell)